04/12/2019 - 06:45 Portfolio
Imcheck Therapeutics raises USD 53 million, Gimv increases its investment in the immuno-oncology space
Welcome to our investor area where you can access all shareholder information on Gimv. Our latest press releases, reports, presentations and financial calendar are available to view and download, as well as the historical archive of previous content.
On 21 June both the 7-year bonds (the "2026 bonds") and the 12-year bonds (the "2031 bonds") were substantially oversubscribed and closed.
With a persistent strong pace of investment, Gimv grew its portfolio further to its present level of EUR 1.2 billion. Together with the realised capital gains on exits, this gave us again a strong portfolio return of 15% (annualised).
Good corporate governance is essential to sustaining successful companies’ growth. We are keen to be exemplary in this respect.